» Articles » PMID: 26646849

Low Intratumoral Regulatory T Cells and High Peritumoral CD8(+) T Cells Relate to Long-term Survival in Patients with Pancreatic Ductal Adenocarcinoma After Pancreatectomy

Overview
Date 2015 Dec 10
PMID 26646849
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

The prognosis for pancreatic ductal adenocarcinoma (PDAC) remains extremely poor. Recent studies have focused on the role of lymphocytes in the PDAC microenvironment. Using immunohistochemistry, our study explored the clinical significance of intratumoral or peritumoral CD4(+)Foxp3(+) regulatory T cells (Tregs) and CD8(+) T cells in the tumor microenvironment and analyzed their relation to the prognosis of PDAC in a consecutive series of 92 patients after resection. CD8(+) T cells were more frequently seen within peritumoral sites, while CD4(+)Foxp3(+) Tregs were more frequent within intratumoral areas. Neither exhibited any relationship with other clinicopathologic factors. Patients with low levels of intratumoral Tregs had longer disease-free survival than those with higher levels (DFS 22.2 vs. 11.2 months, p < 0.001), and patients with higher levels of peritumoral CD8(+) T cells had longer overall survival than those with lower levels (OS 31.0 vs. 14.2 months, p < 0.001). Multivariate analysis demonstrated that intratumoral Tregs (hazard ratio, HR 3.39, p = 0.010) and peritumoral CD8(+) T cells (HR 0.10, p < 0.001) are related to DFS and OS, respectively. These results indicate that intratumoral Tregs are a negative predictor of DFS, while peritumoral CD8(+) T cells are a positive predictor of OS for PDAC patients with pancreatectomy.

Citing Articles

TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion.

Debesset A, Pilon C, Meunier S, Cuelenaere-Bonizec O, Richer W, Thiolat A J Immunother Cancer. 2024; 12(11).

PMID: 39562007 PMC: 11580249. DOI: 10.1136/jitc-2024-008898.


Noncoding Ribonucleic Acids (RNAs) May Improve Response to Immunotherapy in Pancreatic Cancer.

Ala M ACS Pharmacol Transl Sci. 2024; 7(9):2557-2572.

PMID: 39296265 PMC: 11406708. DOI: 10.1021/acsptsci.3c00394.


FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma.

Liu S, Weng J, Cao M, Zhou Q, Xu M, Xu W Oncologist. 2024; 29(12):e1734-e1747.

PMID: 38986528 PMC: 11630758. DOI: 10.1093/oncolo/oyae170.


The causal effects of immune cells on pancreatic cancer: A 2‑sample Mendelian randomization study.

Zou X, Shen J, Yong X, Diao Y, Zhang L Medicine (Baltimore). 2024; 103(16):e37797.

PMID: 38640310 PMC: 11029941. DOI: 10.1097/MD.0000000000037797.


Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.

Rupp L, Dietsche I, Kiessler M, Sommer U, Muckenhuber A, Steiger K Front Immunol. 2024; 15:1378190.

PMID: 38629072 PMC: 11018975. DOI: 10.3389/fimmu.2024.1378190.


References
1.
Hiraoka N, Onozato K, Kosuge T, Hirohashi S . Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006; 12(18):5423-34. DOI: 10.1158/1078-0432.CCR-06-0369. View

2.
Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

3.
Kontani K, Sawai S, Hanaoka J, Tezuka N, Inoue S, Fujino S . Involvement of granzyme B and perforin in suppressing nodal metastasis of cancer cells in breast and lung cancers. Eur J Surg Oncol. 2001; 27(2):180-6. DOI: 10.1053/ejso.2000.1060. View

4.
Bindea G, Mlecnik B, Fridman W, Galon J . The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011; 33(4):335-40. PMC: 3139059. DOI: 10.1007/s00281-011-0264-x. View

5.
Homma Y, Taniguchi K, Murakami T, Nakagawa K, Nakazawa M, Matsuyama R . Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2013; 21(2):670-6. DOI: 10.1245/s10434-013-3390-y. View